Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
Key Takeaways Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.The companies plan to provide further details about the research at a scientific forum in 2025.
Teva, Sanofi say bowel disease drug met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.
Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals. Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD),
Teva Stock Soars on Early Bowel Disease Drug Data
Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug experienced clinical remission, compared with 20.5% who received a placebo.
Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
US affiliate and partner Sanofi (SNY) said Tuesday that a phase 2b study of Teva's investigational duvakitug drug to treat ulcerative colitis and Crohn's disease met its primary endpoints. Ulcerative colitis and Crohn's disease are the most common types of inflammatory bowel disease.
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...
A Game Plan for Your Moderate-to-Severe Ulcerative Colitis
The symptoms of UC are unpredictable. On a given day it can cause an urge to use the bathroom repeatedly, or blood in your ...
The Lancet4h
Guselkumab in the IL-23 inhibition landscape for ulcerative colitis
The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum with a relapsing–remitting course, has been a long and challenging journey, ...
Medindia3d
Beta Ionone: A New Hope for Ulcerative Colitis Patients
Discover how β-ionone offers relief from ulcerative colitis by enhancing gut health, reducing inflammation, and restoring ...
clinicaladvisor.com6d
Ulcerative Colitis Statistics
Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment.
Irish Independent on MSN5d
Crohn’s and colitis are not fun at Christmas, but new cookbook offers gut-friendly recipes to avoid flare-ups
At Christmas people with Crohn’s disease and ­colitis can often be left at risk of a digestive flare-up as they are tempted ...
Los Angeles Magazine13d
Local Gala Raises Half a Million for Crohn's and Colitis Research
Courtesy of Crohn’s & Colitis Foundation Los Angeles/Orange County Chapter The Crohn's & Colitis Foundation's Los Angeles ...
PharmiWeb13h
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...
FierceBiotech14h
Sanofi, Teva look to 'next frontier' in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...